Do You Know

03-05-2023 : 769 Pharmacists work as Medical Representative, of which 39 work as Senior Medical Representative * 02-06-2020 : 216 non Pharmacists work as Medical Representative, and 54 work as Senior Medical Representative * 05-06-2023 : In Lebanon, 88 generic medicinal products are more expensive than their Originators * 31-12-2019 : A medicinal product refused in Europe is marketed in Lebanon * 05-06-2023 : At least 332 medicinal products are available on the Lebanese market and are not available in the country of origin * 05-06-2023 : The price of the most expensive medicine available in Lebanon is 30434557 LL * 05-06-2023 : At least 1309 medicinal products are more expensive in Lebanon than in the countries of origin * 01-01-2019 : Daktavira, a generic of Daklinza, is registered in Lebanon but has no public price * 31-12-2019 : 352 medicinal products have been declared as non-marketed or withdrawn * 09-11-2021 : 64.72% of lebanese pharmacists are female * 31-12-2019 : 486 medicines were submitted to the Ministry of Health for a marketing authorization, and 514 medicines were registered to date * 15-06-2018 : The Minister of Public Health, has decided to suspend the commercialization of AB Slim (Ab Care Medical Herbs), which contains sibutramine, sildenafil and phenolphthalein * 01-06-2020 : Some Non-Marketed medicines are still imported * 01-06-2020 : Ixempra, a medicinal product withdrawn in Europe is imported to lebanon * 01-06-2020 : A vaccine made in India, removed from WHO list of prequalified vaccines, is submitted for registration in Lebanon * 01-06-2020 : Lebanon has 14 CROs, and is ranked as one of the largest countries in the world in clinical studies. According to the WHO, 817 clinical studies are currently conducted in Lebanon. * 05-01-2021 : * 01-10-2023 : Adakveo is now withdrawn from use in the European Union due to lack of therapeutic efficacy *

Products » Items » NovoSeven RT 100KIU


To avoid
As a precautionary measure

Contraindicated
NovoSeven RT 100KIU :
Type Medicine Authorised
Originator Biotech (NovoSeven RT 100KIU)
Agent Mersaco
Distributor Mersaco
Laboratory Novo Nordisk
Responsible Party Novo Nordisk AS
Origin Denmark
Manufacturer Novo Nordisk AS
Origin Denmark
ATC B02BD08

Your comment will appear shortly after approval

NovoSeven RT 100KIU :

Revision Date : 18/12/2013


Effect Frequency
ALT increased Rare
Anaphylactic reactions Not known
Angina pectoris Rare
Angioedema (Angioneurotic oedema) (Quincke oedema) Not known
Antithrombin III decreased Rare
Blood alkaline phosphatase increased Rare
Blood lactate dehydrogenase increased Rare
Cardiac arrest Not known
Cerebral artery occlusion Rare
Cerebral infarction Rare
Cerebral ischaemia Rare
Cerebrovascular accident Rare
Coagulopathy Rare
Deep vein thrombosis Uncommon
Dermatitis allergic Uncommon
Disseminated intravascular coagulation Rare
Drug ineffective Not known
Fibrin D dimer increased Rare
Fibrin degradation products increased Rare
Flushing Not known
Headache Rare
Hypersensitivity Rare
Inhibiting antibodies Not known
Injection site pain Rare
Injection site reaction Rare
Intestinal ischaemia Rare
Intracardiac thrombus Not known
Myocardial infarction Rare
Nausea Rare
Peripheral artery thrombosis Rare
Peripheral ischaemia Rare
Portal vein thrombosis Uncommon
Prothrombin level increased Rare
Pruritus Uncommon
Pulmonary embolism Uncommon
Pyrexia Uncommon
Rash erythematous Uncommon
Renal artery thrombosis Rare
Renal vein thrombosis Uncommon
Skin rash Uncommon
Therapeutic response decreased Uncommon
Thromboembolic event Uncommon
Thromboembolism arterial Rare
Thromboembolism venous Uncommon
Thrombophlebitis Uncommon
Thrombophlebitis superficial Uncommon
Urticaria Uncommon
Vessel puncture site thrombosis Uncommon

Different Units By MoH Code

Revision Date : 11/01/2013

NovoSeven RT 100KIU  MoH 5539 :
Form Powder and solvent for solution for injection
Packaging Pre-filled Syringes + Vials (Type I glass)
Package Size 1+1
Strength 2mg (100KIU)
Public Price 1689135 L.L.
Stratum E2
NSSF ✔
Quarantine ✘
Reg. Number 218018/09
Submission date 01/01/2009
Registration Year 2009


Price Comparison

● Country: Italy
● Package Size: 1+1x2.1ml
● Public Price: 2158.24 EUR ( 209,081,658.24 LBP )
● Pack size unit used: 1
● Cost/Unit: 2158,24 EUR ( 209,058,408.00 LBP )
● Exfactory Price: 1307.7 EUR
● Pricing Date: 17/12/2019
● Type: Medicine Authorised

● Country: Qatar
● Package Size: 1
● Public Price: 7927 QAR ( 194,671,266.00 LBP )
● Pack size unit used: 1
● Cost/Unit: 7927 QAR ( 194,671,266.00 LBP )
● Pharmacy Price: 6510.94417298 QAR ( 159895767.00004 LBP )
● Pricing Date: 28/01/2021
● Type: Medicine Authorised

● Country: Oman
● Package Size: 1+1
● Public Price: 834.57 OMR ( 192,563,674.38 LBP )
● Pack size unit used: 1
● Cost/Unit: 834,57 OMR ( 192,432,156.00 LBP )
● Pricing Date: 19/02/2021
● Type: Medicine Authorised

● Country: Kuweit
● Package Size: 1+1
● Public Price: 638.4 KWD ( 187,422,110.40 LBP )
● Pack size unit used: 1
● Cost/Unit: 638,4 KWD ( 187,304,678.00 LBP )
● Pharmacy Price: 539.34 KWD ( 158339976.54 LBP )
● Pricing Date: 07/02/2021
● Type: Medicine Authorised

● Country: Switzerland
● Package Size: 1+1
● Public Price: 1774.15 CHF ( 183,482,593.00 LBP )
● Pack size unit used: 1
● Cost/Unit: 1774,15 CHF ( 183,467,080.00 LBP )
● Exfactory Price: 1690.88 CHF
● Pricing Date: 04/04/2021
● Type: Medicine Authorised

● Country: Abu Dhabi
● Package Size: 1+1x2.1ml
● Public Price: 7406.5 AED ( 178,948,446.50 LBP )
● Pack size unit used: 1
● Cost/Unit: 7406,5 AED ( 178,936,366.00 LBP )
● Pharmacy Price: 6309.52 AED ( 152444312.72 LBP )
● Pricing Date: 27/01/2021
● Type: Medicine Authorised

● Country: UAE
● Package Size: 1 Vial (Powder) + 1 Solvent Vial (2.1ml)
● Public Price: 7406.5 AED ( 178,948,446.50 LBP )
● Pack size unit used: 1
● Cost/Unit: 7406,5 AED ( 178,936,366.00 LBP )
● Pharmacy Price: 6309.52 AED ( 152444312.72 LBP )
● Pricing Date: 21/08/2019
● Type: Medicine Authorised

● Country: Bahrain
● Package Size: 1+1
● Public Price: 704.5 BHD ( 167,483,603.00 LBP )
● Pack size unit used: 1
● Cost/Unit: 704,5 BHD ( 167,364,736.00 LBP )
● Reference: nhra
● Pricing Date: 09/02/2021
● Type: Medicine Authorised

● Country: Finland
● Package Size: 1+1x2ml
● Public Price: 1579.45 EUR ( 153,010,798.20 LBP )
● Pack size unit used: 1
● Cost/Unit: 1579,45 EUR ( 152,967,204.00 LBP )
● Reference: Kela
● Pricing Date: 22/04/2021
● Type: Medicine Authorised

● Country: Iceland
● Package Size: 1+1
● Public Price: 216970 ISK ( 139,945,650.00 LBP )
● Pack size unit used: 1
● Cost/Unit: 216970 ISK ( 139,945,650.00 LBP )
● Pharmacy Price: 169345 ISK ( 109227525 LBP )
● Reference: Icelandic Medicines Agency
● Pricing Date: 01/04/2020
● Type: Medicine Authorised

● Country: Denmark
● Package Size: 1+1
● Public Price: 10629.4 DKK ( 137,927,094.40 LBP )
● Pack size unit used: 1
● Cost/Unit: 10629,4 DKK ( 137,921,904.00 LBP )
● Pharmacy Price: 7897.84 DKK ( 102482371.84 LBP )
● Reference: Danish Medicine Agency
● Pricing Date: 19/05/2021
● Type: Medicine Authorised

● Country: Czech Republic
● Package Size: 1+1x2ml
● Public Price: 34221.93 CZK ( 130,693,550.67 LBP )
● Pack size unit used: 1
● Cost/Unit: 34221,93 CZK ( 130,689,999.00 LBP )
● Reference: SUKL
● Pricing Date: 28/02/2020
● Type: Medicine Authorised

● Country: KSA
● Package Size: 2mg
● Public Price: 5290.4 SAR ( 125,065,056.00 LBP )
● Pack size unit used: 1
● Cost/Unit: 5290,4 SAR ( 125,055,600.00 LBP )
● Reference: sfda
● Pricing Date: 16/01/2021
● Type: Medicine Authorised

● Country: Cyprus
● Package Size: 1 x 2ml
● Public Price: 1263.97 EUR ( 122,448,357.72 LBP )
● Pack size unit used: 1
● Cost/Unit: 1263,97 EUR ( 122,354,388.00 LBP )
● Reference: Cyprus Minister of Health
● Pricing Date: 24/03/2021
● Type: Medicine Authorised

● Country: Greece
● Package Size: 1+1
● Public Price: 1260.19 EUR ( 122,082,166.44 LBP )
● Pack size unit used: 1
● Cost/Unit: 1260,19 EUR ( 122,063,760.00 LBP )
● Exfactory Price: 1115.49 EUR
● Pharmacy Price: 1132.25 EUR ( 109687851 LBP )
● Reference: National Organization for Medicines
● Pricing Date: 25/02/2021
● Type: Medicine Authorised

● Country: UK
● Package Size: 1+1
● Public Price: 1050.4 GBP ( 119,376,909.60 LBP )
● Pack size unit used: 1
● Cost/Unit: 1050,4 GBP ( 119,331,450.00 LBP )
● Reference: DMD
● Pricing Date: 08/03/2021
● Type: Medicine Authorised

● Country: Spain
● Package Size: 1 vial + 1xdisolvente
● Public Price: 1220.48 EUR ( 118,235,220.48 LBP )
● Pack size unit used: 1
● Cost/Unit: 1220,48 EUR ( 118,188,720.00 LBP )
● Reference: Agencia Española de Medicamentos y Productos Sanitarios
● Pricing Date: 06/05/2021
● Type: Medicine Non Marketed

● Country: France
● Package Size: 1+1
● Public Price: 1216 EUR ( 117,801,216.00 LBP )
● Pack size unit used: 1
● Cost/Unit: 1216 EUR ( 117,801,216.00 LBP )
● Reference: ansm
● Pricing Date: 15/05/2021
● Type: Medicine Authorised

● Country: Belgium
● Package Size: 1+1x2.1ml
● Public Price: 1065 EUR ( 103,172,940.00 LBP )
● Pack size unit used: 1
● Cost/Unit: 1065 EUR ( 103,172,940.00 LBP )
● Reference: cbip
● Pricing Date: 02/12/2020
● Type: Medicine Authorised

● Country: Norway
● Package Size: 1
● Public Price: 12060.5 NOK ( 97,738,292.00 LBP )
● Pack size unit used: 1
● Cost/Unit: 12060,5 NOK ( 97,734,240.00 LBP )
● Pharmacy Price: 9430.82 NOK ( 76427365.28 LBP )
● Reference: Norwegian Medicine Agency
● Pricing Date: 01/04/2020
● Type: Medicine Authorised

● Country: Sweden
● Package Size: 1+1
● Public Price: 11420.85 SEK ( 96,026,506.80 LBP )
● Pack size unit used: 1
● Cost/Unit: 11420,85 SEK ( 96,019,360.00 LBP )
● Pharmacy Price: 11151.57 SEK ( 93762400.56 LBP )
● Pricing Date: 23/04/2020
● Type: Medicine Authorised

● Country: Turkey
● Package Size: 1
● Public Price: 5801.16 TRY ( 15,547,108.80 LBP )
● Pack size unit used: 1
● Cost/Unit: 5801,16 TRY ( 15,546,680.00 LBP )
● Pricing Date: 28/10/2020
● Type: Medicine Authorised

● Country: Lebanon
● Form: Powder and solvent for solution for injection
● Package Size: 1+1
● Public Price: 1689135 LBP ( 1,689,135.00 LBP )
● Pack size unit used: 1
● Cost/Unit: 1689135 LBP ( 1,689,135.00 LBP )
● Pricing Date: 13/06/2024

● Country: The Netherlands
● Package Size: 1
● Reference: Zorginstituut Nederland
● Pricing Date: 15/06/2019
● Type: Medicine Non Marketed

● Country: New Zealand
● Package Size: 1 inj
● Exfactory Price: 2356.6 NZD
● Reference: New Zealand Pharmaceutical Management Agency
● Pricing Date: 01/04/2020
● Type: Medicine Authorised

● Country: Portugal
● Package Size: 1+1
● Reference: Autoridade Nacional do Medicamento e Produtos de Saúde
● Pricing Date: 22/04/2019

    ◼ Lebanon
    ◼ Country of Origin
    ◼ Reference Countries
    ◼ Other Countries

Note

Acquired haemophilia :
● Cost/Unit: 2158,24 EUR ( 209,058,408.00 LBP )
● Cost/Day: 6474,72 EUR ( 627,175,224.00 LBP )
● Cost/Month: 6474,72 EUR ( 627,175,224.00 LBP )
Congenital FVII deficiency :
● Cost/Unit: 2158,24 EUR ( 209,058,408.00 LBP )
● Cost/Day: 6474,72 EUR ( 627,175,224.00 LBP )
● Cost/Month: 6474,72 EUR ( 627,175,224.00 LBP )
Congenital haemophilia with inhibitors to coagulation factors IX :
● Cost/Unit: 2158,24 EUR ( 209,058,408.00 LBP )
● Cost/Day: 6474,72 EUR ( 627,175,224.00 LBP )
● Cost/Month: 6474,72 EUR ( 627,175,224.00 LBP )
Congenital haemophilia with inhibitors to coagulation factors VIII :
● Cost/Unit: 2158,24 EUR ( 209,058,408.00 LBP )
● Cost/Day: 6474,72 EUR ( 627,175,224.00 LBP )
● Cost/Month: 6474,72 EUR ( 627,175,224.00 LBP )
Glanzmann’s thrombasthenia with antibodies to GP IIb - IIIa and/or HLA : (Adults)
● Cost/Unit: 2158,24 EUR ( 209,058,408.00 LBP )
● Cost/Day: 6474,72 EUR ( 627,175,224.00 LBP )
● Cost/Month: 6474,72 EUR ( 627,175,224.00 LBP )
Acquired haemophilia :
● Cost/Unit: 7927 QAR ( 194,671,266.00 LBP )
● Cost/Day: 23781 QAR ( 584,013,798.00 LBP )
● Cost/Month: 23781 QAR ( 584,013,798.00 LBP )
Congenital FVII deficiency :
● Cost/Unit: 7927 QAR ( 194,671,266.00 LBP )
● Cost/Day: 23781 QAR ( 584,013,798.00 LBP )
● Cost/Month: 23781 QAR ( 584,013,798.00 LBP )
Congenital haemophilia with inhibitors to coagulation factors IX :
● Cost/Unit: 7927 QAR ( 194,671,266.00 LBP )
● Cost/Day: 23781 QAR ( 584,013,798.00 LBP )
● Cost/Month: 23781 QAR ( 584,013,798.00 LBP )
Congenital haemophilia with inhibitors to coagulation factors VIII :
● Cost/Unit: 7927 QAR ( 194,671,266.00 LBP )
● Cost/Day: 23781 QAR ( 584,013,798.00 LBP )
● Cost/Month: 23781 QAR ( 584,013,798.00 LBP )
Glanzmann’s thrombasthenia with antibodies to GP IIb - IIIa and/or HLA : (Adults)
● Cost/Unit: 7927 QAR ( 194,671,266.00 LBP )
● Cost/Day: 23781 QAR ( 584,013,798.00 LBP )
● Cost/Month: 23781 QAR ( 584,013,798.00 LBP )
Acquired haemophilia :
● Cost/Unit: 834,57 OMR ( 192,432,156.00 LBP )
● Cost/Day: 2503,71 OMR ( 577,527,202.00 LBP )
● Cost/Month: 2503,71 OMR ( 577,527,202.00 LBP )
Congenital FVII deficiency :
● Cost/Unit: 834,57 OMR ( 192,432,156.00 LBP )
● Cost/Day: 2503,71 OMR ( 577,527,202.00 LBP )
● Cost/Month: 2503,71 OMR ( 577,527,202.00 LBP )
Congenital haemophilia with inhibitors to coagulation factors IX :
● Cost/Unit: 834,57 OMR ( 192,432,156.00 LBP )
● Cost/Day: 2503,71 OMR ( 577,527,202.00 LBP )
● Cost/Month: 2503,71 OMR ( 577,527,202.00 LBP )
Congenital haemophilia with inhibitors to coagulation factors VIII :
● Cost/Unit: 834,57 OMR ( 192,432,156.00 LBP )
● Cost/Day: 2503,71 OMR ( 577,527,202.00 LBP )
● Cost/Month: 2503,71 OMR ( 577,527,202.00 LBP )
Glanzmann’s thrombasthenia with antibodies to GP IIb - IIIa and/or HLA : (Adults)
● Cost/Unit: 834,57 OMR ( 192,432,156.00 LBP )
● Cost/Day: 2503,71 OMR ( 577,527,202.00 LBP )
● Cost/Month: 2503,71 OMR ( 577,527,202.00 LBP )
Acquired haemophilia :
● Cost/Unit: 638,4 KWD ( 187,304,678.00 LBP )
● Cost/Day: 1915,2 KWD ( 562,207,615.00 LBP )
● Cost/Month: 1915,2 KWD ( 562,207,615.00 LBP )
Congenital FVII deficiency :
● Cost/Unit: 638,4 KWD ( 187,304,678.00 LBP )
● Cost/Day: 1915,2 KWD ( 562,207,615.00 LBP )
● Cost/Month: 1915,2 KWD ( 562,207,615.00 LBP )
Congenital haemophilia with inhibitors to coagulation factors IX :
● Cost/Unit: 638,4 KWD ( 187,304,678.00 LBP )
● Cost/Day: 1915,2 KWD ( 562,207,615.00 LBP )
● Cost/Month: 1915,2 KWD ( 562,207,615.00 LBP )
Congenital haemophilia with inhibitors to coagulation factors VIII :
● Cost/Unit: 638,4 KWD ( 187,304,678.00 LBP )
● Cost/Day: 1915,2 KWD ( 562,207,615.00 LBP )
● Cost/Month: 1915,2 KWD ( 562,207,615.00 LBP )
Glanzmann’s thrombasthenia with antibodies to GP IIb - IIIa and/or HLA : (Adults)
● Cost/Unit: 638,4 KWD ( 187,304,678.00 LBP )
● Cost/Day: 1915,2 KWD ( 562,207,615.00 LBP )
● Cost/Month: 1915,2 KWD ( 562,207,615.00 LBP )
Acquired haemophilia :
● Cost/Unit: 1774,15 CHF ( 183,467,080.00 LBP )
● Cost/Day: 5322,45 CHF ( 550,401,240.00 LBP )
● Cost/Month: 5322,45 CHF ( 550,401,240.00 LBP )
Congenital FVII deficiency :
● Cost/Unit: 1774,15 CHF ( 183,467,080.00 LBP )
● Cost/Day: 5322,45 CHF ( 550,401,240.00 LBP )
● Cost/Month: 5322,45 CHF ( 550,401,240.00 LBP )
Congenital haemophilia with inhibitors to coagulation factors IX :
● Cost/Unit: 1774,15 CHF ( 183,467,080.00 LBP )
● Cost/Day: 5322,45 CHF ( 550,401,240.00 LBP )
● Cost/Month: 5322,45 CHF ( 550,401,240.00 LBP )
Congenital haemophilia with inhibitors to coagulation factors VIII :
● Cost/Unit: 1774,15 CHF ( 183,467,080.00 LBP )
● Cost/Day: 5322,45 CHF ( 550,401,240.00 LBP )
● Cost/Month: 5322,45 CHF ( 550,401,240.00 LBP )
Glanzmann’s thrombasthenia with antibodies to GP IIb - IIIa and/or HLA : (Adults)
● Cost/Unit: 1774,15 CHF ( 183,467,080.00 LBP )
● Cost/Day: 5322,45 CHF ( 550,401,240.00 LBP )
● Cost/Month: 5322,45 CHF ( 550,401,240.00 LBP )
Acquired haemophilia :
● Cost/Unit: 7406,5 AED ( 178,936,366.00 LBP )
● Cost/Day: 22219,5 AED ( 536,833,259.00 LBP )
● Cost/Month: 22219,5 AED ( 536,833,259.00 LBP )
Congenital FVII deficiency :
● Cost/Unit: 7406,5 AED ( 178,936,366.00 LBP )
● Cost/Day: 22219,5 AED ( 536,833,259.00 LBP )
● Cost/Month: 22219,5 AED ( 536,833,259.00 LBP )
Congenital haemophilia with inhibitors to coagulation factors IX :
● Cost/Unit: 7406,5 AED ( 178,936,366.00 LBP )
● Cost/Day: 22219,5 AED ( 536,833,259.00 LBP )
● Cost/Month: 22219,5 AED ( 536,833,259.00 LBP )
Congenital haemophilia with inhibitors to coagulation factors VIII :
● Cost/Unit: 7406,5 AED ( 178,936,366.00 LBP )
● Cost/Day: 22219,5 AED ( 536,833,259.00 LBP )
● Cost/Month: 22219,5 AED ( 536,833,259.00 LBP )
Glanzmann’s thrombasthenia with antibodies to GP IIb - IIIa and/or HLA : (Adults)
● Cost/Unit: 7406,5 AED ( 178,936,366.00 LBP )
● Cost/Day: 22219,5 AED ( 536,833,259.00 LBP )
● Cost/Month: 22219,5 AED ( 536,833,259.00 LBP )
Acquired haemophilia :
● Cost/Unit: 7406,5 AED ( 178,936,366.00 LBP )
● Cost/Day: 22219,5 AED ( 536,833,259.00 LBP )
● Cost/Month: 22219,5 AED ( 536,833,259.00 LBP )
Congenital FVII deficiency :
● Cost/Unit: 7406,5 AED ( 178,936,366.00 LBP )
● Cost/Day: 22219,5 AED ( 536,833,259.00 LBP )
● Cost/Month: 22219,5 AED ( 536,833,259.00 LBP )
Congenital haemophilia with inhibitors to coagulation factors IX :
● Cost/Unit: 7406,5 AED ( 178,936,366.00 LBP )
● Cost/Day: 22219,5 AED ( 536,833,259.00 LBP )
● Cost/Month: 22219,5 AED ( 536,833,259.00 LBP )
Congenital haemophilia with inhibitors to coagulation factors VIII :
● Cost/Unit: 7406,5 AED ( 178,936,366.00 LBP )
● Cost/Day: 22219,5 AED ( 536,833,259.00 LBP )
● Cost/Month: 22219,5 AED ( 536,833,259.00 LBP )
Glanzmann’s thrombasthenia with antibodies to GP IIb - IIIa and/or HLA : (Adults)
● Cost/Unit: 7406,5 AED ( 178,936,366.00 LBP )
● Cost/Day: 22219,5 AED ( 536,833,259.00 LBP )
● Cost/Month: 22219,5 AED ( 536,833,259.00 LBP )
Acquired haemophilia :
● Cost/Unit: 704,5 BHD ( 167,364,736.00 LBP )
● Cost/Day: 2113,5 BHD ( 502,331,942.00 LBP )
● Cost/Month: 2113,5 BHD ( 502,331,942.00 LBP )
Congenital FVII deficiency :
● Cost/Unit: 704,5 BHD ( 167,364,736.00 LBP )
● Cost/Day: 2113,5 BHD ( 502,331,942.00 LBP )
● Cost/Month: 2113,5 BHD ( 502,331,942.00 LBP )
Congenital haemophilia with inhibitors to coagulation factors IX :
● Cost/Unit: 704,5 BHD ( 167,364,736.00 LBP )
● Cost/Day: 2113,5 BHD ( 502,331,942.00 LBP )
● Cost/Month: 2113,5 BHD ( 502,331,942.00 LBP )
Congenital haemophilia with inhibitors to coagulation factors VIII :
● Cost/Unit: 704,5 BHD ( 167,364,736.00 LBP )
● Cost/Day: 2113,5 BHD ( 502,331,942.00 LBP )
● Cost/Month: 2113,5 BHD ( 502,331,942.00 LBP )
Glanzmann’s thrombasthenia with antibodies to GP IIb - IIIa and/or HLA : (Adults)
● Cost/Unit: 704,5 BHD ( 167,364,736.00 LBP )
● Cost/Day: 2113,5 BHD ( 502,331,942.00 LBP )
● Cost/Month: 2113,5 BHD ( 502,331,942.00 LBP )
Acquired haemophilia :
● Cost/Unit: 1579,45 EUR ( 152,967,204.00 LBP )
● Cost/Day: 4738,35 EUR ( 458,998,488.00 LBP )
● Cost/Month: 4738,35 EUR ( 458,998,488.00 LBP )
Congenital FVII deficiency :
● Cost/Unit: 1579,45 EUR ( 152,967,204.00 LBP )
● Cost/Day: 4738,35 EUR ( 458,998,488.00 LBP )
● Cost/Month: 4738,35 EUR ( 458,998,488.00 LBP )
Congenital haemophilia with inhibitors to coagulation factors IX :
● Cost/Unit: 1579,45 EUR ( 152,967,204.00 LBP )
● Cost/Day: 4738,35 EUR ( 458,998,488.00 LBP )
● Cost/Month: 4738,35 EUR ( 458,998,488.00 LBP )
Congenital haemophilia with inhibitors to coagulation factors VIII :
● Cost/Unit: 1579,45 EUR ( 152,967,204.00 LBP )
● Cost/Day: 4738,35 EUR ( 458,998,488.00 LBP )
● Cost/Month: 4738,35 EUR ( 458,998,488.00 LBP )
Glanzmann’s thrombasthenia with antibodies to GP IIb - IIIa and/or HLA : (Adults)
● Cost/Unit: 1579,45 EUR ( 152,967,204.00 LBP )
● Cost/Day: 4738,35 EUR ( 458,998,488.00 LBP )
● Cost/Month: 4738,35 EUR ( 458,998,488.00 LBP )
Acquired haemophilia :
● Cost/Unit: 216970 ISK ( 139,945,650.00 LBP )
● Cost/Day: 650910 ISK ( 419,836,950.00 LBP )
● Cost/Month: 650910 ISK ( 419,836,950.00 LBP )
Congenital FVII deficiency :
● Cost/Unit: 216970 ISK ( 139,945,650.00 LBP )
● Cost/Day: 650910 ISK ( 419,836,950.00 LBP )
● Cost/Month: 650910 ISK ( 419,836,950.00 LBP )
Congenital haemophilia with inhibitors to coagulation factors IX :
● Cost/Unit: 216970 ISK ( 139,945,650.00 LBP )
● Cost/Day: 650910 ISK ( 419,836,950.00 LBP )
● Cost/Month: 650910 ISK ( 419,836,950.00 LBP )
Congenital haemophilia with inhibitors to coagulation factors VIII :
● Cost/Unit: 216970 ISK ( 139,945,650.00 LBP )
● Cost/Day: 650910 ISK ( 419,836,950.00 LBP )
● Cost/Month: 650910 ISK ( 419,836,950.00 LBP )
Glanzmann’s thrombasthenia with antibodies to GP IIb - IIIa and/or HLA : (Adults)
● Cost/Unit: 216970 ISK ( 139,945,650.00 LBP )
● Cost/Day: 650910 ISK ( 419,836,950.00 LBP )
● Cost/Month: 650910 ISK ( 419,836,950.00 LBP )
Acquired haemophilia :
● Cost/Unit: 10629,4 DKK ( 137,921,904.00 LBP )
● Cost/Day: 31888,2 DKK ( 413,778,688.00 LBP )
● Cost/Month: 31888,2 DKK ( 413,778,688.00 LBP )
Congenital FVII deficiency :
● Cost/Unit: 10629,4 DKK ( 137,921,904.00 LBP )
● Cost/Day: 31888,2 DKK ( 413,778,688.00 LBP )
● Cost/Month: 31888,2 DKK ( 413,778,688.00 LBP )
Congenital haemophilia with inhibitors to coagulation factors IX :
● Cost/Unit: 10629,4 DKK ( 137,921,904.00 LBP )
● Cost/Day: 31888,2 DKK ( 413,778,688.00 LBP )
● Cost/Month: 31888,2 DKK ( 413,778,688.00 LBP )
Congenital haemophilia with inhibitors to coagulation factors VIII :
● Cost/Unit: 10629,4 DKK ( 137,921,904.00 LBP )
● Cost/Day: 31888,2 DKK ( 413,778,688.00 LBP )
● Cost/Month: 31888,2 DKK ( 413,778,688.00 LBP )
Glanzmann’s thrombasthenia with antibodies to GP IIb - IIIa and/or HLA : (Adults)
● Cost/Unit: 10629,4 DKK ( 137,921,904.00 LBP )
● Cost/Day: 31888,2 DKK ( 413,778,688.00 LBP )
● Cost/Month: 31888,2 DKK ( 413,778,688.00 LBP )
Acquired haemophilia :
● Cost/Unit: 34221,93 CZK ( 130,689,999.00 LBP )
● Cost/Day: 102665,79 CZK ( 392,077,635.00 LBP )
● Cost/Month: 102665,79 CZK ( 392,077,635.00 LBP )
Congenital FVII deficiency :
● Cost/Unit: 34221,93 CZK ( 130,689,999.00 LBP )
● Cost/Day: 102665,79 CZK ( 392,077,635.00 LBP )
● Cost/Month: 102665,79 CZK ( 392,077,635.00 LBP )
Congenital haemophilia with inhibitors to coagulation factors IX :
● Cost/Unit: 34221,93 CZK ( 130,689,999.00 LBP )
● Cost/Day: 102665,79 CZK ( 392,077,635.00 LBP )
● Cost/Month: 102665,79 CZK ( 392,077,635.00 LBP )
Congenital haemophilia with inhibitors to coagulation factors VIII :
● Cost/Unit: 34221,93 CZK ( 130,689,999.00 LBP )
● Cost/Day: 102665,79 CZK ( 392,077,635.00 LBP )
● Cost/Month: 102665,79 CZK ( 392,077,635.00 LBP )
Glanzmann’s thrombasthenia with antibodies to GP IIb - IIIa and/or HLA : (Adults)
● Cost/Unit: 34221,93 CZK ( 130,689,999.00 LBP )
● Cost/Day: 102665,79 CZK ( 392,077,635.00 LBP )
● Cost/Month: 102665,79 CZK ( 392,077,635.00 LBP )
Acquired haemophilia :
● Cost/Unit: 5290,4 SAR ( 125,055,600.00 LBP )
● Cost/Day: 15871,2 SAR ( 375,190,440.00 LBP )
● Cost/Month: 15871,2 SAR ( 375,190,440.00 LBP )
Congenital FVII deficiency :
● Cost/Unit: 5290,4 SAR ( 125,055,600.00 LBP )
● Cost/Day: 15871,2 SAR ( 375,190,440.00 LBP )
● Cost/Month: 15871,2 SAR ( 375,190,440.00 LBP )
Congenital haemophilia with inhibitors to coagulation factors IX :
● Cost/Unit: 5290,4 SAR ( 125,055,600.00 LBP )
● Cost/Day: 15871,2 SAR ( 375,190,440.00 LBP )
● Cost/Month: 15871,2 SAR ( 375,190,440.00 LBP )
Congenital haemophilia with inhibitors to coagulation factors VIII :
● Cost/Unit: 5290,4 SAR ( 125,055,600.00 LBP )
● Cost/Day: 15871,2 SAR ( 375,190,440.00 LBP )
● Cost/Month: 15871,2 SAR ( 375,190,440.00 LBP )
Glanzmann’s thrombasthenia with antibodies to GP IIb - IIIa and/or HLA : (Adults)
● Cost/Unit: 5290,4 SAR ( 125,055,600.00 LBP )
● Cost/Day: 15871,2 SAR ( 375,190,440.00 LBP )
● Cost/Month: 15871,2 SAR ( 375,190,440.00 LBP )
Acquired haemophilia :
● Cost/Unit: 1263,97 EUR ( 122,354,388.00 LBP )
● Cost/Day: 3791,91 EUR ( 367,256,916.00 LBP )
● Cost/Month: 3791,91 EUR ( 367,256,916.00 LBP )
Congenital FVII deficiency :
● Cost/Unit: 1263,97 EUR ( 122,354,388.00 LBP )
● Cost/Day: 3791,91 EUR ( 367,256,916.00 LBP )
● Cost/Month: 3791,91 EUR ( 367,256,916.00 LBP )
Congenital haemophilia with inhibitors to coagulation factors IX :
● Cost/Unit: 1263,97 EUR ( 122,354,388.00 LBP )
● Cost/Day: 3791,91 EUR ( 367,256,916.00 LBP )
● Cost/Month: 3791,91 EUR ( 367,256,916.00 LBP )
Congenital haemophilia with inhibitors to coagulation factors VIII :
● Cost/Unit: 1263,97 EUR ( 122,354,388.00 LBP )
● Cost/Day: 3791,91 EUR ( 367,256,916.00 LBP )
● Cost/Month: 3791,91 EUR ( 367,256,916.00 LBP )
Glanzmann’s thrombasthenia with antibodies to GP IIb - IIIa and/or HLA : (Adults)
● Cost/Unit: 1263,97 EUR ( 122,354,388.00 LBP )
● Cost/Day: 3791,91 EUR ( 367,256,916.00 LBP )
● Cost/Month: 3791,91 EUR ( 367,256,916.00 LBP )
Acquired haemophilia :
● Cost/Unit: 1260,19 EUR ( 122,063,760.00 LBP )
● Cost/Day: 3780,57 EUR ( 366,191,280.00 LBP )
● Cost/Month: 3780,57 EUR ( 366,191,280.00 LBP )
Congenital FVII deficiency :
● Cost/Unit: 1260,19 EUR ( 122,063,760.00 LBP )
● Cost/Day: 3780,57 EUR ( 366,191,280.00 LBP )
● Cost/Month: 3780,57 EUR ( 366,191,280.00 LBP )
Congenital haemophilia with inhibitors to coagulation factors IX :
● Cost/Unit: 1260,19 EUR ( 122,063,760.00 LBP )
● Cost/Day: 3780,57 EUR ( 366,191,280.00 LBP )
● Cost/Month: 3780,57 EUR ( 366,191,280.00 LBP )
Congenital haemophilia with inhibitors to coagulation factors VIII :
● Cost/Unit: 1260,19 EUR ( 122,063,760.00 LBP )
● Cost/Day: 3780,57 EUR ( 366,191,280.00 LBP )
● Cost/Month: 3780,57 EUR ( 366,191,280.00 LBP )
Glanzmann’s thrombasthenia with antibodies to GP IIb - IIIa and/or HLA : (Adults)
● Cost/Unit: 1260,19 EUR ( 122,063,760.00 LBP )
● Cost/Day: 3780,57 EUR ( 366,191,280.00 LBP )
● Cost/Month: 3780,57 EUR ( 366,191,280.00 LBP )
Acquired haemophilia :
● Cost/Unit: 1050,4 GBP ( 119,331,450.00 LBP )
● Cost/Day: 3151,2 GBP ( 358,107,999.00 LBP )
● Cost/Month: 3151,2 GBP ( 358,107,999.00 LBP )
Congenital FVII deficiency :
● Cost/Unit: 1050,4 GBP ( 119,331,450.00 LBP )
● Cost/Day: 3151,2 GBP ( 358,107,999.00 LBP )
● Cost/Month: 3151,2 GBP ( 358,107,999.00 LBP )
Congenital haemophilia with inhibitors to coagulation factors IX :
● Cost/Unit: 1050,4 GBP ( 119,331,450.00 LBP )
● Cost/Day: 3151,2 GBP ( 358,107,999.00 LBP )
● Cost/Month: 3151,2 GBP ( 358,107,999.00 LBP )
Congenital haemophilia with inhibitors to coagulation factors VIII :
● Cost/Unit: 1050,4 GBP ( 119,331,450.00 LBP )
● Cost/Day: 3151,2 GBP ( 358,107,999.00 LBP )
● Cost/Month: 3151,2 GBP ( 358,107,999.00 LBP )
Glanzmann’s thrombasthenia with antibodies to GP IIb - IIIa and/or HLA : (Adults)
● Cost/Unit: 1050,4 GBP ( 119,331,450.00 LBP )
● Cost/Day: 3151,2 GBP ( 358,107,999.00 LBP )
● Cost/Month: 3151,2 GBP ( 358,107,999.00 LBP )
Acquired haemophilia :
● Cost/Unit: 1220,48 EUR ( 118,188,720.00 LBP )
● Cost/Day: 3661,44 EUR ( 354,663,036.00 LBP )
● Cost/Month: 3661,44 EUR ( 354,663,036.00 LBP )
Congenital FVII deficiency :
● Cost/Unit: 1220,48 EUR ( 118,188,720.00 LBP )
● Cost/Day: 3661,44 EUR ( 354,663,036.00 LBP )
● Cost/Month: 3661,44 EUR ( 354,663,036.00 LBP )
Congenital haemophilia with inhibitors to coagulation factors IX :
● Cost/Unit: 1220,48 EUR ( 118,188,720.00 LBP )
● Cost/Day: 3661,44 EUR ( 354,663,036.00 LBP )
● Cost/Month: 3661,44 EUR ( 354,663,036.00 LBP )
Congenital haemophilia with inhibitors to coagulation factors VIII :
● Cost/Unit: 1220,48 EUR ( 118,188,720.00 LBP )
● Cost/Day: 3661,44 EUR ( 354,663,036.00 LBP )
● Cost/Month: 3661,44 EUR ( 354,663,036.00 LBP )
Glanzmann’s thrombasthenia with antibodies to GP IIb - IIIa and/or HLA : (Adults)
● Cost/Unit: 1220,48 EUR ( 118,188,720.00 LBP )
● Cost/Day: 3661,44 EUR ( 354,663,036.00 LBP )
● Cost/Month: 3661,44 EUR ( 354,663,036.00 LBP )
Acquired haemophilia :
● Cost/Unit: 1216 EUR ( 117,801,216.00 LBP )
● Cost/Day: 3648 EUR ( 353,403,648.00 LBP )
● Cost/Month: 3648 EUR ( 353,403,648.00 LBP )
Congenital FVII deficiency :
● Cost/Unit: 1216 EUR ( 117,801,216.00 LBP )
● Cost/Day: 3648 EUR ( 353,403,648.00 LBP )
● Cost/Month: 3648 EUR ( 353,403,648.00 LBP )
Congenital haemophilia with inhibitors to coagulation factors IX :
● Cost/Unit: 1216 EUR ( 117,801,216.00 LBP )
● Cost/Day: 3648 EUR ( 353,403,648.00 LBP )
● Cost/Month: 3648 EUR ( 353,403,648.00 LBP )
Congenital haemophilia with inhibitors to coagulation factors VIII :
● Cost/Unit: 1216 EUR ( 117,801,216.00 LBP )
● Cost/Day: 3648 EUR ( 353,403,648.00 LBP )
● Cost/Month: 3648 EUR ( 353,403,648.00 LBP )
Glanzmann’s thrombasthenia with antibodies to GP IIb - IIIa and/or HLA : (Adults)
● Cost/Unit: 1216 EUR ( 117,801,216.00 LBP )
● Cost/Day: 3648 EUR ( 353,403,648.00 LBP )
● Cost/Month: 3648 EUR ( 353,403,648.00 LBP )
Acquired haemophilia :
● Cost/Unit: 1065 EUR ( 103,172,940.00 LBP )
● Cost/Day: 3195 EUR ( 309,518,820.00 LBP )
● Cost/Month: 3195 EUR ( 309,518,820.00 LBP )
Congenital FVII deficiency :
● Cost/Unit: 1065 EUR ( 103,172,940.00 LBP )
● Cost/Day: 3195 EUR ( 309,518,820.00 LBP )
● Cost/Month: 3195 EUR ( 309,518,820.00 LBP )
Congenital haemophilia with inhibitors to coagulation factors IX :
● Cost/Unit: 1065 EUR ( 103,172,940.00 LBP )
● Cost/Day: 3195 EUR ( 309,518,820.00 LBP )
● Cost/Month: 3195 EUR ( 309,518,820.00 LBP )
Congenital haemophilia with inhibitors to coagulation factors VIII :
● Cost/Unit: 1065 EUR ( 103,172,940.00 LBP )
● Cost/Day: 3195 EUR ( 309,518,820.00 LBP )
● Cost/Month: 3195 EUR ( 309,518,820.00 LBP )
Glanzmann’s thrombasthenia with antibodies to GP IIb - IIIa and/or HLA : (Adults)
● Cost/Unit: 1065 EUR ( 103,172,940.00 LBP )
● Cost/Day: 3195 EUR ( 309,518,820.00 LBP )
● Cost/Month: 3195 EUR ( 309,518,820.00 LBP )
Acquired haemophilia :
● Cost/Unit: 12060,5 NOK ( 97,734,240.00 LBP )
● Cost/Day: 36181,5 NOK ( 293,210,824.00 LBP )
● Cost/Month: 36181,5 NOK ( 293,210,824.00 LBP )
Congenital FVII deficiency :
● Cost/Unit: 12060,5 NOK ( 97,734,240.00 LBP )
● Cost/Day: 36181,5 NOK ( 293,210,824.00 LBP )
● Cost/Month: 36181,5 NOK ( 293,210,824.00 LBP )
Congenital haemophilia with inhibitors to coagulation factors IX :
● Cost/Unit: 12060,5 NOK ( 97,734,240.00 LBP )
● Cost/Day: 36181,5 NOK ( 293,210,824.00 LBP )
● Cost/Month: 36181,5 NOK ( 293,210,824.00 LBP )
Congenital haemophilia with inhibitors to coagulation factors VIII :
● Cost/Unit: 12060,5 NOK ( 97,734,240.00 LBP )
● Cost/Day: 36181,5 NOK ( 293,210,824.00 LBP )
● Cost/Month: 36181,5 NOK ( 293,210,824.00 LBP )
Glanzmann’s thrombasthenia with antibodies to GP IIb - IIIa and/or HLA : (Adults)
● Cost/Unit: 12060,5 NOK ( 97,734,240.00 LBP )
● Cost/Day: 36181,5 NOK ( 293,210,824.00 LBP )
● Cost/Month: 36181,5 NOK ( 293,210,824.00 LBP )
Acquired haemophilia :
● Cost/Unit: 11420,85 SEK ( 96,019,360.00 LBP )
● Cost/Day: 34262,55 SEK ( 288,074,896.00 LBP )
● Cost/Month: 34262,55 SEK ( 288,074,896.00 LBP )
Congenital FVII deficiency :
● Cost/Unit: 11420,85 SEK ( 96,019,360.00 LBP )
● Cost/Day: 34262,55 SEK ( 288,074,896.00 LBP )
● Cost/Month: 34262,55 SEK ( 288,074,896.00 LBP )
Congenital haemophilia with inhibitors to coagulation factors IX :
● Cost/Unit: 11420,85 SEK ( 96,019,360.00 LBP )
● Cost/Day: 34262,55 SEK ( 288,074,896.00 LBP )
● Cost/Month: 34262,55 SEK ( 288,074,896.00 LBP )
Congenital haemophilia with inhibitors to coagulation factors VIII :
● Cost/Unit: 11420,85 SEK ( 96,019,360.00 LBP )
● Cost/Day: 34262,55 SEK ( 288,074,896.00 LBP )
● Cost/Month: 34262,55 SEK ( 288,074,896.00 LBP )
Glanzmann’s thrombasthenia with antibodies to GP IIb - IIIa and/or HLA : (Adults)
● Cost/Unit: 11420,85 SEK ( 96,019,360.00 LBP )
● Cost/Day: 34262,55 SEK ( 288,074,896.00 LBP )
● Cost/Month: 34262,55 SEK ( 288,074,896.00 LBP )
Acquired haemophilia :
● Cost/Unit: 5801,16 TRY ( 15,546,680.00 LBP )
● Cost/Day: 17403,48 TRY ( 46,640,040.00 LBP )
● Cost/Month: 17403,48 TRY ( 46,640,040.00 LBP )
Congenital FVII deficiency :
● Cost/Unit: 5801,16 TRY ( 15,546,680.00 LBP )
● Cost/Day: 17403,48 TRY ( 46,640,040.00 LBP )
● Cost/Month: 17403,48 TRY ( 46,640,040.00 LBP )
Congenital haemophilia with inhibitors to coagulation factors IX :
● Cost/Unit: 5801,16 TRY ( 15,546,680.00 LBP )
● Cost/Day: 17403,48 TRY ( 46,640,040.00 LBP )
● Cost/Month: 17403,48 TRY ( 46,640,040.00 LBP )
Congenital haemophilia with inhibitors to coagulation factors VIII :
● Cost/Unit: 5801,16 TRY ( 15,546,680.00 LBP )
● Cost/Day: 17403,48 TRY ( 46,640,040.00 LBP )
● Cost/Month: 17403,48 TRY ( 46,640,040.00 LBP )
Glanzmann’s thrombasthenia with antibodies to GP IIb - IIIa and/or HLA : (Adults)
● Cost/Unit: 5801,16 TRY ( 15,546,680.00 LBP )
● Cost/Day: 17403,48 TRY ( 46,640,040.00 LBP )
● Cost/Month: 17403,48 TRY ( 46,640,040.00 LBP )
Acquired haemophilia :
● Cost/Unit: 1689135 LBP ( 1,689,135.00 LBP )
● Cost/Day: 5067405 LBP ( 5,067,405.00 LBP )
● Cost/Month: 5067405 LBP ( 5,067,405.00 LBP )
Congenital FVII deficiency :
● Cost/Unit: 1689135 LBP ( 1,689,135.00 LBP )
● Cost/Day: 5067405 LBP ( 5,067,405.00 LBP )
● Cost/Month: 5067405 LBP ( 5,067,405.00 LBP )
Congenital haemophilia with inhibitors to coagulation factors IX :
● Cost/Unit: 1689135 LBP ( 1,689,135.00 LBP )
● Cost/Day: 5067405 LBP ( 5,067,405.00 LBP )
● Cost/Month: 5067405 LBP ( 5,067,405.00 LBP )
Congenital haemophilia with inhibitors to coagulation factors VIII :
● Cost/Unit: 1689135 LBP ( 1,689,135.00 LBP )
● Cost/Day: 5067405 LBP ( 5,067,405.00 LBP )
● Cost/Month: 5067405 LBP ( 5,067,405.00 LBP )
Glanzmann’s thrombasthenia with antibodies to GP IIb - IIIa and/or HLA : (Adults)
● Cost/Unit: 1689135 LBP ( 1,689,135.00 LBP )
● Cost/Day: 5067405 LBP ( 5,067,405.00 LBP )
● Cost/Month: 5067405 LBP ( 5,067,405.00 LBP )
Prices are provided in Dollar ($)
You have to register to view this info

You have to register to view this info

You have to register to view this info